We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Biogen has entered a collaboration with Stoke ... zorevunersen targets the sodium voltage-gated channel alpha subunit 1(SCN1A) gene, which is the primary cause of most Dravet syndrome cases.

Its MS segment is the largest but also has been losing momentum as 2024 revenues slipped 9% YoY to $1.07 billion. In Q4 2024, Biogen reported $3.44 per share earnings, which beat consensus analyst ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

The results are an early endorsement of Biogen's recent $1.8 billion buyout of Human Immunology Biosciences (HI-Bio), part of a pivot towards immunology programmes to complement its focus on ...

but Biogen now says it will surrender its near-50% stake in the JV. The US biotech stands to receive $1 billion in cash at the close of the deal, with another $1.25 billion due in two instalments ...